林城

作者: 时间:2023-03-31 点击数:

基本信息

姓名:林城

职称:主治医师

单位、科室:福建省肿瘤医院、放疗科

研究方向:食管癌、肺癌等基础研究及其临床转化应用,生物信息学分析

电子邮件:happygo1988@sina.com

个人简介

林城,放疗科主治医师,博士,师从著名肿瘤学专家潘建基教授。福建省肿瘤医院高层次人才,优秀青年人才。主要从事肺癌、食管癌等胸部肿瘤的放射治疗及综合治疗。兼任福建省抗癌协会第二届肿瘤内科专业委员会青委会委员,福建省海峡肿瘤防治科技交流协会肿瘤整合专业委员会委员。

近年专注于食管癌、肺癌、鼻咽癌等恶性肿瘤的基础研究,及其临床转化应用。作为项目负责人,主持省厅级等课题6项,累计经费大于100万。以第一或通讯作者(含共同)发表国内外论著20篇,含中科院1区2篇(1区top期刊Journal of Experimental & Clinical Cancer Research),中科院2区8篇,总影响因子大于50分,总他引大于200余次。

主要科研项目

1.福建省自然科学基金项目(面上项目),2024J011081,肿瘤相关成纤维细胞外泌体蛋白DR5通过诱导铁死亡介导食管鳞癌发生发展的分子机制研究, 2024-11至2027-11,主持。

2.福建省肿瘤医院高层次人才,2024YNG11,100万,2024.01至2028.12,主持。

3.福建省卫生健康中青年骨干人才培养项目, 2020GGB010, EB病毒miR-BART8-3p调控FCHO1参与鼻咽癌免疫抑制的机制研究, 2021-01 至 2023-12, 主持。

4.福建省自然科学基金项目(青创项目), 2020J05071, 泛素连接酶RNF38介导 ACTN4泛素化调控鼻咽癌细胞增殖和凋亡的分子机制研究, 2020-08 至 2023-08,主持。

5.福建省科技创新联合资金项目(引领项目), 2019Y9037, RNF38调控EPLIN对抑制 鼻咽癌转移的作用及机制研究, 2020-09 至 2023-08, 15万元,主持。

6.福建医科大学启航基金项目, 2019QH1192, 血浆EB病毒miR-BART8-3p检测在辅助鼻咽 癌诊疗的临床意义研究, 2020-04 至 2023-04,主持。

7.国家自然科学基金委员会,面上项目,82373200,EBV BART lncRNA靶向IKZF3促进EB病毒在鼻咽癌细胞中潜伏感染的研究, 2024-01-01至2027-12-31,参与。

8.国家自然科学基金委员会, 面上项目, 82173051, YY1调控超级增强子驱动FAM201A过表达介导食管鳞 癌放射抗拒的分子机制研究, 2022-01-01 至 2025-12-31,参与。

9.国家自然科学基金委员会, 面上项目, 81972717, SOX4调控超级增强子驱动EBV BART过表达促进鼻咽癌转移的分子机制研究, 2020-01-01 至 2023-12-31,参与。

10.国家自然科学基金委员会, 联合基金项目, U1705282, 新型光/声动力纳米药物的构建、双模态成像与协同抗肿瘤效应, 2018-01-01 至 2021-12-31, 参与。

获奖经历

1.2023年,第四届福建省抗癌协会科技进步奖二等奖(第一完成人)

2.2024年,第五届福建省抗癌协会科技进步奖二等奖(第四完成人)

3.2024年,福建医学科技奖二等奖(第四完成人)

获得专利

1.一种放射治疗用定位固定架, 2021-12-17,中国, ZL 2021 2 0241110.2

2.一种用于放射治疗的报警装置,2021-12-17,中国, ZL 2021 2 0338681.8

3.一种肿瘤放疗头颈保护装置, 2022-12-09,中国,ZL 2022 2 0532154.5

4.血浆检测试剂转运装置, 2023-11-24,中国, ZL 2023 2 1691867.7

发表的主要论文

(1)Lin Cheng; Zong Jingfeng; Lin Wangsong et al; EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways, Journal of Experimental & Clinical Cancer Research, 2018Nov 26, 37(1): 283.

(2)Lin Cheng; Lin Keyu; Zhang Bin et al; Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma, The Oncologist, 2022Apr 5, 27(4): e340-e349.

(3)Lin Cheng; Li Meifang; Lin Na et al; RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma, BMC Cancer, 2022May 15, 22(1): 549.

(4)Lin Cheng; Chen Yuebing; Pan Jianji et al; Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma, BMC Genomics, 2023Apr 28, 24(1):221.

(5) Lin Cheng; Lin sheng; Zhu lili et al; Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis, BMC Cancer, 2022Jan 4, 22(1): 35.

(6) Lin Cheng; Chen Xiong; Li Meifang et al; Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma, Clinical Lung Cancer, 2015, 16(5): 25-35.

(7) Lin Cheng; Lin Sheng; Guoet al; Systemic immune-inflammation index as a prognostic marker in patients with newly diagnosed metastatic nasopharyngeal carcinoma: a propensity score-matched study. Transl Cancer Res,2019 Sep,8(5), 2089-2098.

(8) Chan Sik Kwan;Lin Cheng; Huang Shao Hui et al; Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncol, 2022Mar, 126: 105736.(共同第一作者)

(9) Li Meifang,Lin Cheng, Lin Jinghui et al. Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutant Advanced NSCLC Beyond Limited Progression on Osimertinib. Anticancer Agents Med Chem, 2023Sep 20, 23(19): 2095-2101.(共同第一作者)

(10) Yuebing Chen, Chuying Chen, Hewei Peng, Shaojun Lin, Jianji Pan, Huiping Zheng, Jingfeng Zong,Cheng Lin. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy. Sci Rep, 2024Feb 17, 14(1):3950.

(11)Cheng Lin, Meifang Li, Yingying Linet al. Impact of plasma Epstein-Barr virus DNA in posttreatment nasopharyngeal carcinoma patients after SARS-CoV-2 infection. Infectious Agents and Cancer, Infectious Agents and Cancer, 2024 Mar 14, 19(1):8.

(12)Cheng Lin, Yuebing Chen, Xiandong Lin et al. Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma. Sci Rep, 2024 May 28, 14(1): 7433.

(13) Yuebing Chen, Yiping Huang, Xiaoqiang Chen, Zhiwei Chen, Xiane Peng, Shaojun Lin,Cheng Lin, Jingfeng Zong. Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma. BMC Cancer, 2024 Apr 16, 24(1):483.(共同通讯作者)

(14)Jianjian Qiu, Zhiping Wang, Yilin Yu, Yangling Zheng, Meifang Li,Cheng Lin. Prognostic and immunological implications of glutathione metabolism genes in lung adenocarcinoma: A focus on the core gene SMS and its impact on M2 macrophage polarization. Int Immunopharmacol, 2024 Apr 8, 132: 111940.

(15)Cheng Lin, Jiani Xiong, Yuebing Chen, Huiping Zheng, Meifang Li. Overexpression of CENPU promotes cancer growth and metastasis and is associated with poor survival in patients with nasopharyngeal carcinoma. Transl Cancer Res, 2024 Jun 30;13(6):2812-2824.

(16)Cheng Lin,Qiongjiao Lu, Yuebing Chen, Xiaoqiang, Chen, Yiping Huang, Hangyan Zhong, Xiane Peng, Cairong Hu, Bijuan Chen, Shaojun Lin, Jingfeng Zong. Failure patterns and individualized treatment plans of reirradiation for inoperable locally recurrent nasopharyngeal carcinoma. 2024 Aug 2. Sci Rep, 14(1): 17887.

Copyright 2022 www.fzu.edu.cn All Rights Reserved.  

研究院地址:福州大学旗山校区国家大学科技园7号楼4-5层东侧